drug · small molecule
iptacopan hydrochloride
Marketedupdated 3mo agoby $NVS NOVARTIS AG🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for paroxysmal nocturnal hemoglobinuria and iga glomerulonephritis and 2 investigational indications.
targets
Complement factor B
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 7, 2027
357 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Jul 15, 2041method-of-use (U-3895)US 11951101
- Jul 15, 2041method-of-use (U-4300)US 12453726
- May 25, 2041compositionUS 11603363
- May 17, 2041method-of-use (U-4161)US 12384758
- Aug 30, 2038method-of-use (U-3980)US 11723901
- Aug 30, 2038method-of-use (U-4181)US 12285422
- Jul 14, 2034method-of-use (U-3980)US 10093663
- Jul 14, 2034compositionUS 9682968
FDA exclusivities (4)
- Dec 5, 2030ODE-456Orphan Drug (7y)4.3y
- Dec 5, 2028NCENew Chemical Entity (5y)2.3y
- Mar 20, 2028I-963Indication (3y)1.6y
- Aug 7, 2027I-949Indication (3y)357d
News(5)
- Vertex unfazed by competitive IgAN space as FDA verdict loomsPositive two-year follow-up data for Otsuka Pharmaceuticals’ IgA nephropathy drug Voyxact could support the FDA’s ongoing review of Vertex Pharmaceuticals’ povetacicept, CEO Reshma Kewalramani said…biospace · 10d ago
- Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide makerBristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.biopharma_dive · 25d ago
- Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvalsThe FDA is currently reviewing Vertex Pharmaceuticals’ povetacicept, with a target action date of Nov. 30. If approved, the drug could benefit from campaigns from Novartis and Vera Therapeutics for…biospace · 25d ago
- Jasper gets a lifeline in merger with immune drugmaker KiraThe acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from setbacks that have wiped out most of its market value.biopharma_dive · 28d ago
- Jasper finds new purpose in merger with Kira, while offloading Tavneos rival to MiradorJasper Therapeutics is being reborn via a merger with Nasdaq-listed immune-mediated disease biotech Kira Pharmaceuticals.fiercebiotech · 28d ago
Data sources
last refreshed 37m ago
Found something off?
comments(0)
5-min edit window · permanent after that